Outsourcing CGT development and manufacturing is a common operational model, but with manufacturing capacity booming across the US and Europe, what is it that CDMOs bring to the table, and what should developers be considering when it comes to meaningful and productive partnership? In this interview, our panelists explore the CDMO landscape as it is in 2025, digging into the commonalities and differences between different approaches to contracted development and manufacturing.

This interview explored key themes rasied during a roundtable on how the blood industry can act as a ‘network of networks’ to support the cell and gene therapy (CGT) field. Key insights from the discussion focused on leveraging the blood industry’s expertise in vascular access, apheresis, and logistics to address challenges such as timing, scalability, and access. Priorities include expanding clinical skills, fostering partnerships with hospitals and CGT developers, and deploying innovative mobile and point-of-care services. By aligning policies, improving collaboration, and addressing capacity gaps, the blood industry can play a pivotal role in advancing patient care and scaling CGT delivery.

Let’s talk CGT investment. IBTV talks to industry experts at ARM’s Meeting on the Mesa about the current financial landscape.

As CGTs are commercialized and operations scale, innovation flourishes with new tools, technologies and processes addressing bottlenecks and challenges inhibiting access. With innovation, however, comes the unknown – how do we ensure that what we’re doing is as safe as possible? In this interview, our panelists challenge the unknown, considering how we might reduce the risk of off-target effects and maintain safety, while maintaining efficiency across the board. Featuring; Georgi Makin IBTV Host, Priya Baraniak - Biotechnology Executive, Heather Purvis - Title21 Health Solutions, Stella Vnook - Likarda and Kevin Land - Vitalant

Investment in CGT has long been an issue up for discussion, as the landscape shifts year-on-year, region-to-region. In this Spotlight interview, our panelists discuss insights from Phacilitate’s Investor Summit, sharing their predictions and expectations for the investment landscape for 2025, and beyond.

Can these two dividing concepts create a working model for the benefit of the patient? In this roundtable round-up, we explore how centralized and decentralized manufacturing can work together to meet the diverse needs of patients and therapies. The panellists discuss practical strategies for finding the right balance; improving efficiency while making sure patients have access to the care they need. Together, the panellists review proposed ways to align manufacturing models with patient-focused outcomes, sparking ideas and collaborations to help drive meaningful progress.

The better the quality of the starting materials, the better the result. But what measures and strategies can be put in place to ensure CGT development and manufacturing is starting from quality materials? In this interview, our panelists discuss various checkpoints, considerations and approaches for assuring quality throughout the starting materials infrastructure, from ensuring quality donors to logistical and delivery processes that all impact the final product, and ultimately, the patient. Georgi Makin, IBTV Hosts Dalip Sethi - Commercial Leader, Cell Therapy Technologies, North America, Terumo Blood and Cell Technologies, Kevin Land - Executive Medical Director, Biotherapies and Vice Present of Clinical Services, Vitalant & Carlos Carballosa - VP Sales, OrganaBio.

As therapies transition from development to commercialization, the journey is shaped by pivotal early-stage decisions - choices that resonate across manufacturing and scalability. In this interview, our panelists navigate the complexities of platform technologies, raw material selection, and process optimization, considering how these decisions can streamline downstream operations.